Dravet Syndrome: Drug Development Pipeline Study, H1 2018

Dravet Syndrome: Drug Development Pipeline Study, H1 2018

  • February 2018 •
  • 46 pages •
  • Report ID: 5320415 •
  • Format: PDF
10 drugs have been assigned with orphan drug designation
The most comprehensive pipeline review “Dravet Syndrome- Drug Development Pipeline Study” provides in-depth analysis and update information on Dravet Syndrome pipeline drugs. Current status of all the drugs in the Dravet Syndrome pipeline is provided in the research work.

Previously known as severe myoclonic epilepsy of infancy (SMEI), the neurological disease is attracting wide interest from pharmaceutical companies over the past five years. In particular, with 10 drugs receiving orphan drug status, the prominence of Dravet Syndrome pipeline is robust.

The report provides detailed analysis of Dravet Syndrome pipeline including companies involved, drugs in different stages of development, drug development details across regions (Region (North America, Europe, Asia Pacific and Rest of the World). Further, the Dravet Syndrome report identifies aspects important in modifying industry market scenarios, increasing opportunities and list of potential companies that impact the Dravet Syndrome industry.

Excerpts from- “Dravet Syndrome- Drug Development Pipeline Study”:
Dravet syndrome is a genetically- modified seizure condition associated with extended, frequent refractory seizures. The condition is also called as severe myoclonic epilepsy of infancy (SMEI). Dravet Syndrome occurs due to defects in SCN1A genes in brain and causes cognitive and behavioral disorders and around 15- 20% death rate.

Seizures start at the age of one, and are frequently associated with febrile convulsions. Subsequently, multiple types of seizures occur such as epilepticus. After the age 2, baby shows signs of deteriorating cognitive and behavioral skills, resulting in long term disability.

US FDA has not approved any drugs and EMA has approved only one drug. Treatment options include Clobazam plus valporate plus stiripentol, which offers only a modest seizure control.

Lack of approved complete treatments for the disease has spurred interest among pharmaceutical companies, in specific over the past few years. As of February 2018, the Dravet syndrome pipeline consists of at least 15 drug candidates, of which 4 are in late stage. Of this, 10 drugs have been given Orphan Drug Designations. This research work reviews the current status of Dravet Syndrome drug development pipeline.

Dravet Syndrome pipeline comprises of 15 drugs under development as of February 2018. Of these, 4 drugs are in Phase 1 and 4 are in phase 2. Further, 3 drugs remain in Phase 3 while one drug has moved into Pre-registration phase. In addition, 3 drugs are in Pre-Clinical Stage.

23 companies/ institutions are developing the pipeline for Dravet Sysndrome.

Scope:
- All latest industry developments and their impact on projects and companies
- Complete overview of global Dravet Syndrome therapy options and treatments
- The pipeline study reviews drug detailss for Dravet Syndrome by developing companies, institutions, mechanism of action, Target, Route, Phase (pre-clinical/ Discovery, Phase 1, Phase 2, Phase 3, Pre-Registration, IND/ NDA), molecule
- Mergers, Acquisitions, licensing, co-development and project acquisition news for Dravet Syndrome market
- Dravet Syndrome drugs being developed in combination with other drugs are also detailed
- Company wise drugs listed

Executive Summary
Dravet syndrome is a genetically- modified seizure condition associated with extended, frequent refractory seizures. The condition is also called as severe myoclonic epilepsy of infancy (SMEI). Dravet Syndrome occurs due to defects in SCN1A genes in brain and causes cognitive and behavioral disorders and around 15- 20% death rate.

Seizures start at the age of one, and are frequently associated with febrile convulsions. Subsequently, multiple types of seizures occur such as epilepticus. After the age 2, baby shows signs of deteriorating cognitive and behavioral skills, resulting in long term disability.

US FDA has not approved any drugs and EMA has approved only one drug. Treatment options include Clobazam plus valporate plus stiripentol, which offers only a modest seizure control.

Lack of approved complete treatments for the disease has spurred interest among pharmaceutical companies, in specific over the past few years. As of February 2018, the Dravet syndrome pipeline consists of at least 15 drug candidates, of which 4 are in late stage. Of this, 10 drugs have been given Orphan Drug Designations. This research work reviews the current status of Dravet Syndrome drug development pipeline.

Dravet Syndrome pipeline comprises of 15 drugs under development as of February 2018. Of these, 4 drugs are in Phase 1 and 4 are in phase 2. Further, 3 drugs remain in Phase 3 while one drug has moved into Pre-registration phase. In addition, 3 drugs are in Pre-Clinical Stage.

23 companies/ institutions are developing the pipeline for Dravet Sysndrome.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.